Kirkland, United States
Cardiac Dimensions, founded in 2001 and headquartered in the United States, is at the forefront of providing innovative solutions for patients with heart failure. The company positions itself under the bold mission of "Reshaping the Course of Heart Failure®".
At the heart of their offerings is the Carillon Mitral Contour System®, a non-surgical device offering a unique approach to treating mitral valve insufficiency. Unlike traditional therapies, Carillon stands out as the only indirect, no-touch option that not only addresses symptoms but also reshapes the heart's anatomy, enhancing longevity and quality of life for patients. Additionally, it can be combined with other heart failure treatments, demonstrating versatility.
The latest funding round, a $35.00M Series D investment on 05 January 2023, saw participation from notable investors like Arboretum Ventures, Hostplus, Lumira Ventures, M. H. Carnegie, and Horizon 3. This strong financial backing underscores confidence in their pioneering technology, projecting substantial growth potential within the Biotechnology, Health Care, and Medical Devices industries.
MitrAssist
